Clinical Trial Update: Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating 611, a recombinant anti-IL-4 receptor alpha monoclonal antibody, in Chinese adults with moderate-to-severe atopic dermatitis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• 611 (Recombinant Humanized Anti-Interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody)

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Dermatitis, Atopic | Phase 3 | Status: COMPLETED